Valeritas (NASDAQ:VLRX) and Soliton (NASDAQ:SOLY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
17.2% of Valeritas shares are held by institutional investors. Comparatively, 9.5% of Soliton shares are held by institutional investors. 1.0% of Valeritas shares are held by insiders. Comparatively, 10.0% of Soliton shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Valeritas and Soliton’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Valeritas and Soliton’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Valeritas||$26.40 million||0.49||-$45.93 million||($34.20)||-0.05|
Soliton has lower revenue, but higher earnings than Valeritas.
This is a breakdown of recent recommendations and price targets for Valeritas and Soliton, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valeritas presently has a consensus price target of $13.00, indicating a potential upside of 733.33%. Given Valeritas’ higher possible upside, analysts clearly believe Valeritas is more favorable than Soliton.
Soliton beats Valeritas on 5 of the 9 factors compared between the two stocks.
Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.
Soliton, Inc., an early stage medical device company, focuses on developing and commercializing products using a proprietary rapid acoustic pulse technology platform. It offers a device for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.